- Harmony Acquisitions Corp. and Vimy Pharmaceuticals signed a non-binding letter of intent to complete a reverse takeover, which will serve as Harmony’s Qualifying Transaction on the TSX Venture Exchange. Following the deal, the combined company is expected to be renamed Vimy Pharmaceuticals Corp., while Harmony’s shares remain halted pending completion.
- Alongside the transaction, Vimy Pharma has engaged Beacon Securities to lead a concurrent financing, with additional details on the transaction and financing to be disclosed in a future announcement.
- Vimy Pharma is focused on affordable generic medicines and strengthening Canadian pharmaceutical manufacturing. Earlier this year, it filed an Abbreviated New Drug Submission (ANDS) with Health Canada for a generic version of Ozempic (semaglutide), which has been accepted for review.
- The company plans to manufacture semaglutide domestically with Canadian partners while expanding into international markets. Led by former Novo Nordisk executives, Vimy aims to improve access to affordable therapies and strengthen Canada’s long-term pharmaceutical supply resilience.
Takeaways:
By combining a TSXV listing with a Health Canada-accepted ANDS for a domestically made generic Ozempic, Vimy is positioning itself to compete in a fast-growing, high-value GLP-1 market where Canadian production and supply-security arguments can resonate with payers, governments, and health systems. If approval and launch timelines hold, the company could capture share in a CAD$3.5 billion semaglutide market that is still expanding, but it will face intense competition from multiple other generic applicants and established brands, so execution on manufacturing, pricing, and distribution will be the real differentiator.
Source: CA Newswire
